The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Open accessAbstract
Background Drug treatments for patients with high-risk myelodysplastic syndromes provide no survival advantage. In this trial, we aimed to assess the effect of azacitidine on overall survival compared with the three commonest conventional care regimens.Methods In a phase III, international, multicentre, controlled, parallel-group, open-label trial, patients with higher-risk myelodysplastic syndromes were randomly assigned one-to-one to receive azacitidine (75 mg/m(2) per day for 7 days every 28 days) or conventional care (best supportive care, low-dose cytarabine, or intensive chemotherapy as selected by investigators before randomisation). Patients were stratified by French-American-British and international prognostic scoring system classifications; randomisation was done with a block size of four. The primary endpoint was overall survival. Efficacy analyses were by intention to treat for all patients assigned to receive treatment. This study is registered with ClinicalTrials.gov, number NCT00071799.Findings Between Feb 13, 2004, and Aug 7, 2006, 358 patients were randomly assigned to receive azacitidine (n=179) or conventional care regimens (n=179). Four patients in the azacitidine and 14 in the conventional care groups received no study drugs but were included in the intention-to-treat efficacy analysis. After a median follow-up of 21.1 months (IQR 15.1-26.9), median overall survival was 24.5 months (9.9-not reached) for the azacitidine group versus 15.0 months (5.6-24.1) for the conventional care group (hazard ratio 0.58; 95% CI 0.43-0.77; stratified log-rank p=0.0001). At last follow-up, 82 patients in the azacitidine group had died compared with 113 in the conventional care group. At 2 years, on the basis of Kaplan-Meier estimates, 50.8% (95% CI 42.1-58.8) of patients in the azacitidine group were alive compared with 26.2% (18.7-34.3) in the conventional care group (p<0.0001). Peripheral cytopenias were the most common grade 3-4 adverse events for all treatments.Interpretation Treatment with azacitidine increases overall survival in patients with higher-risk myelodysplastic syndromes relative to conventional care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypomethylating agents (HMAs), such as azacitidine and decitabine, yield statistically similar complete remission (CR) rates of approximately 15%-20% in patients with either TP53-mutant or wild-type MDS.12-14”
From Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Adverse events were similar to those reported for azacitidine or eprenetapopt monotherapy, with the most common grade ≥ 3 adverse events being febrile neutropenia (33%), leukopenia (29%), and neutropenia (29%).”
From Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredIn the citing paper
“Whilst response rates of up to 60% to azacytidine have been reported in MDS 125,129 ,”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [129]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,236
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,516
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Self-citationProposals for the classification of the myelodysplastic syndromes
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb08475.x · Cited by 3,619
Self-citationHarris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G., Müller‐Hermelink, H. K., Vardiman, J. W., Lister, T. A., & Bloomfield, C. D. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.12.3835 · Cited by 3,261
Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Döhner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,686
Self-citationDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Cited by
Sorted by citations
Items 201–300 of 1,002
Fraison, J. B., MEKINIAN, A., Grignano, É., Kahn, J., Arlet, J., Decaux, O., Denis, G., Buchdahl, A.-L., Omouri, M., Maigné, G., et al. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.02.005 · Cited by 113
Self-citationRautenberg, C., Germing, U., Haas, R. R., Kobbe, G., & Schroeder, T. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010228 · Cited by 113
Advances in DNA methylation: 5-hydroxymethylcytosine revisited
Dahl, C., Grønbæk, K., & Guldberg, P. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.02.013 · Cited by 117
Epigenetics in hepatocellular carcinoma: An update and future therapy perspectives
Ma, L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i2.333 · Cited by 114
EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression
Renneville, A., van Galen, P., Canver, M. C., McConkey, M. E., Krill-Burger, J. M., Dorfman, D. M., Holson, E. B., Bernstein, B., Orkin, S. H., Bauer, D. E., et al. (2015) · Blood · doi:10.1182/blood-2015-06-649087 · Cited by 111
How I treat chronic myelomonocytic leukemia
Solary, É., & Itzykson, R. (2017) · Blood · doi:10.1182/blood-2017-04-736421 · Cited by 112
Myelodysplastic syndromes: moving towards personalized management
Hellström‐Lindberg, E., Tobiasson, M., & Greenberg, P. L. (2020) · Haematologica · doi:10.3324/haematol.2020.248955 · Cited by 109
Jabbour, E. J., Garcia‐Manero, G., Strati, P., Mishra, A., Ali, N. H. A., Padron, E., Lancet, J. E., Kadia, T. M., Daver, N. G., O'Brien, S. M., et al. (2014) · Cancer · doi:10.1002/cncr.29145 · Cited by 111
Self-citationAcute Myeloid Leukemia: The Good, the Bad, and the Ugly
Kuykendall, A. T., Duployez, N., Boissel, N., Lancet, J. E., & Welch, J. S. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_199519 · Cited by 115
Dao, K.-H. T., Gotlib, J. R., Deininger, M. W., Oh, S. T., Cortes, J. E., Collins, R. H., Winton, E. F., Parker, D., Lee, H., Schultz, A. R., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00895 · Cited by 112
Pavletic, S. Z., Kumar, S. K., Mohty, M., Lima, M. J. G. D., Foran, J. M., Pasquini, M. C., Zhang, M., Giralt, S., Bishop, M. R., & Weisdorf, D. J. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.04.004 · Cited by 111
“An ‘‘inverse’’ selection bias may send fewer early MDS patients to alloHSCT because of available hypomethylating agents or lenalidomide [90-92].”
Recent developments in epigenetics of acute and chronic kidney diseases
Reddy, M. A., & Natarajan, R. D. (2015) · Kidney International · doi:10.1038/ki.2015.148 · Cited by 115
Sekeres, M. A., List, A. F., Cuthbertson, D. D., PAQUETTE, R. L., Ganetsky, R., Latham, D., Paulic, K., Afable, M. G., Saba, H. I., Loughran, T. P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.0745 · Cited by 109
“improves overall survival in patients with higher-risk MDS or oligoblastic acute myeloid leukemia (AML) when compared with patients treated with conventional care.(18) The next frontier in MDS therapeutics is to combine active agents with different mechanisms of action, particularly in higher-risk disease, for which b…”
ResultInfluentialSelf-citationMyelodysplastic syndromes: 2015 Update on diagnosis, risk‐stratification and management
Garcia‐Manero, G. (2015) · American Journal of Hematology · doi:10.1002/ajh.24102 · Cited by 112
Gurion, R., Vidal, L., Gafter-Gvili, A., Belnik, Y., Yeshurun, M., Raanani, P., & Shpilberg, O. (2009) · Haematologica · doi:10.3324/haematol.2009.010611 · Cited by 109
Bernal, T., Martínez‐Camblor, P., Sánchez‐García, J., de Paz, R., Luño, E., Nomdedeu, B., Ardanaz, M., Pedro, C., Amigo, M. L., Xicoy, B., et al. (2015) · Leukemia · doi:10.1038/leu.2015.115 · Cited by 108
Self-citationvan der Helm, L. H., Alhan, C., Wijermans, P., Kooy, M. V. M., Schaafsma, R., Biemond, B. J., Beeker, A., Hoogendoorn, M., van Rees, B. P., de Weerdt, O., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08893.x · Cited by 108
“A recent Phase 3 study demonstrated that azacitidine significantly improved overall survival (OS) in higher-risk MDS patients when compared with conventional care regimens (Fenaux et al, 2009).”
BackgroundResultSekeres, M. A., Watts, J. M., Radinoff, A., Sangerman, M. A., Cerrano, M., Font, P., Zeidner, J. F., Díez‐Campelo, M., Graux, C., Liesveld, J. L., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01125-4 · Cited by 112
Naqvi, K., Jabbour, E. J., Bueso-Ramos, C., Pierce, S. A., Borthakur, G. M., Estrov, Z. E., Ravandi, F., Faderl, S. H., Kantarjian, H. M., & Garcia‐Manero, G. (2011) · Blood · doi:10.1182/blood-2011-03-342642 · Cited by 107
Carney, D. A., Westerman, D., Tam, C. S. L., Milner, A., Prince, H. M., Kenealy, M. K., Wolf, M., Januszewicz, E. H., Ritchie, D., Came, N. A., et al. (2010) · Leukemia · doi:10.1038/leu.2010.218 · Cited by 107
Self-citationGarcia‐Manero, G., Montalban‐Bravo, G., Berdeja, J. G., Abaza, Y., Jabbour, E., Essell, J., Lyons, R. M., Ravandi, F., Maris, M., Heller, B., et al. (2017) · Cancer · doi:10.1002/cncr.30533 · Cited by 104
“5 [1-47] Platelet count, 310(9)/L 39 [2-1370] 54 [15-701]”
Chatterjee, R., & Vinson, C. (2012) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2012.02.014 · Cited by 109
Mutations of myelodysplastic syndromes (MDS): An update
Ganguly, B. B., & Kadam, N. N. (2016) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2016.04.009 · Cited by 108
Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy
Uy, G. L., Duncavage, E. J., Chang, G. S., Jacoby, M. A., Miller, C. A., Shao, J., Heath, S. C., Elliott, K., Reineck, T., Fulton, R. S., et al. (2016) · Leukemia · doi:10.1038/leu.2016.282 · Cited by 108
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?
Loke, J. C. T., Buka, R. J., & Craddock, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.659595 · Cited by 119
Azacitidine for the treatment of lower risk myelodysplastic syndromes
Musto, P., Maurillo, L., Spagnoli, A., Gozzini, A., Rivellini, F., Lunghi, M., Villani, O., Spiriti, M. A. A., Venditti, A., & Santini, V. (2010) · Cancer · doi:10.1002/cncr.24894 · Cited by 107
“Recent data also have demonstrated that azacitidine is the first agent to induce a significant survival advantage compared with conventional care regimens in patients with higher risk MDS.(36) Most previous studies of azacitidine in patients with MDS, however, included only a very small proportion of those with lower…”
BackgroundResultSelf-citationSaber, W., Cutler, C. S., Nakamura, R., Zhang, M., Atallah, E. L., Rizzo, J. D., Maziarz, R. T., Cortes, J. E., Kalaycio, M. E., & Horowitz, M. M. (2013) · Blood · doi:10.1182/blood-2013-04-496778 · Cited by 104
Xu, F., Li, X., Wu, L., Zhang, Q., Yang, R., Yang, Y., Zhang, Z., He, Q., & Chang, C. (2010) · Annals of Hematology · doi:10.1007/s00277-010-1128-5 · Cited by 103
Wei, G., Ni, W., Chiao, J.-W., Cai, Z., Huang, H., & Liu, D. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-46 · Cited by 103
“Fenaux [33] MDS 358 38-88 69 Azacitidine CCR 17 8 11(4) 9(4) NR”
BackgroundHow we treat higher-risk myelodysplastic syndromes
Sekeres, M. A., & Cutler, C. S. (2013) · Blood · doi:10.1182/blood-2013-08-496935 · Cited by 102
An evolutionary perspective on chronic myelomonocytic leukemia
Itzykson, R., & Solary, É. (2013) · Leukemia · doi:10.1038/leu.2013.100 · Cited by 108
Yue, J., Lv, D., Wang, C., Li, L., Zhao, Q., Chen, H., & Xu, L. (2018) · Oncogene · doi:10.1038/s41388-018-0276-2 · Cited by 102
“It is noteworthy that 5-azacytidine has been studied extensively and shown promising antitumor activity in vivo and is being evaluated for its potential clinical significance [43, 44].”
Kröger, N., Sockel, K., Wolschke, C., Bethge, W. A., Schlenk, R. F., Wolf, D. G. F., Stadler, M., Kobbe, G., Wulf, G. G., Bug, G., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02724 · Cited by 102
“A randomized trial that compared 5-aza with best available therapy demonstrated an improvedOS for patients treatedwith 5-aza.(8) Comparative studies with HSCT especially in elderly patients are needed.”
ResultSelf-citationVoso, M. T., Santini, V., Finelli, C., Musto, P., Pogliani, E., Angelucci, E., Fioritoni, G., Alimena, G., Maurillo, L., Cortelezzi, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0494 · Cited by 102
Self-citationObba, S., Hizir, Z., Boyer, L., Selimoglu-Buet, D., Pfeifer, A., Michel, G., Hamouda, M.-A., Gonçalvès, D., Cerezo, M., Marchetti, S., et al. (2015) · Autophagy · doi:10.1080/15548627.2015.1034406 · Cited by 100
“Nevertheless, the data presented herein deciphers the signaling pathways involved in CSF1-mediated induction of autophagy and monocyte differentiation, as well as paves a new research avenue for future therapeutic interventions through PRKAA reactivation in the context of CMML. Patients were newly diagnosed or had pre…”
BackgroundInfluentialAzacitidine in untreated acute myeloid leukemia: A report on 149 patients
Thépot, S., Itzykson, R., Seegers, V., Récher, C., Raffoux, E., Quesnel, B., Delaunay, J., Cluzeau, T., Marfaing‐Koka, A., Stamatoullas, A., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23654 · Cited by 101
“Interestingly, and as also observed in higher risk MDS treated with AZA [9,10,12], age, a strong determinant of outcome in older AML patients when treated intensively, did not influence OS in this AZA AML cohort, possibly due to the more limited myelosuppression associated with AZA compared to intensive chemotherapy.”
ResultSelf-citationAutoimmune manifestations associated with myelodysplastic syndromes
Grignano, É., Jachiet, V., Fenaux, P., Adès, L., Fain, O., & MEKINIAN, A. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3472-9 · Cited by 105
Self-citationThe myelodysplastic syndrome as a prototypical epigenetic disease
Issa, J. J. (2013) · Blood · doi:10.1182/blood-2013-02-451757 · Cited by 103
Padron, E., Dezern, A. E., Andrade‐Campos, M., Vaddi, K., Scherle, P., Zhang, Q., Ma, Y., Balasis, M. E., Tinsley, S., Ramadan, H., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2781 · Cited by 102
“Although theDNA hypomethylating agents (HMA) azacitidine and decitabine are approved for use in CMML by the FDA, a paucity of CMML patients were included in registration trials, and no treatment has been shown to impact the natural history of this disease (2).”
Self-citationChronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management
Patnaik, M. M., & Tefferi, A. (2022) · American Journal of Hematology · doi:10.1002/ajh.26455 · Cited by 102
“The pivotal North American CALGB study (n = 191) only included 14 CMML patients; 7 being assigned to the 5-azacitidine arm and 7 to the best supportive care (BSC) arm,109 while the European AZA-001 study, only included 11 patients with CMML (all MDS-CMML), with 6 being assigned to the 5-azacitidine arm and 5 being ass…”
BackgroundLübbert, M., Bertz, H., Wäsch, R., Marks, R., Rüter, B. H., Claus, R., & Finke, J. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.222 · Cited by 99
Guillaume, T., Malard, F., Magro, L., Labopin, M., Tabrizi, R., Borel, C., Chevallier, P., Vigouroux, S., Péterlin, P., Garnier, A., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0536-y · Cited by 99
How we manage adults with myelodysplastic syndrome
Fenaux, P., Platzbecker, U., & Adès, L. (2019) · British Journal of Haematology · doi:10.1111/bjh.16206 · Cited by 103
“In a randomised phase 3 clinical trial in higher-risk MDS patients, a survival benefit with azacitidine was demonstrated over conventional care regimens (Fenaux et al, 2009), with a median survival of 24 4 months compared to 15 months.”
BackgroundInfluentialSelf-citationReduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice
Muto, H., Sakata‐Yanagimoto, M., Nagae, G., Shiozawa, Y., Miyake, Y., Yoshida, K., Enami, T., Kamada, Y., Kato, T., Uchida, K., et al. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2014.83 · Cited by 101
Cowan, L. A., Talwar, S., & Yang, A. S. (2010) · Epigenomics · doi:10.2217/epi.09.44 · Cited by 97
Pleyer, L., Burgstaller, S., Girschikofsky, M., Linkesch, W., Stauder, R., Pfeilstöcker, M., Schreder, M., Tinchon, C., Sliwa, T., Lang, A. H., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2126-9 · Cited by 97
“6 months and the high overall response rates (48 % ITT) seem remarkable, particularly since (i) the registry included many elderly (43 % ≥75 years), comorbid (79 %), and/or pretreated patients (62 %); (ii) 33 % of patients received ≤2 cycles of azacitidine (reasons therefore listed in the “Results” section); (iii) 82…”
BackgroundMethodNovel Approaches to the Treatment of Acute Myeloid Leukemia
Roboz, G. J. (2011) · Hematology · doi:10.1182/asheducation-2011.1.43 · Cited by 103
Predicting response to epigenetic therapy
Treppendahl, M. B., Kristensen, L. S., & Grønbæk, K. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69737 · Cited by 97
“However, conflicting results exist, with another study showing gender-specific differences in overall survival (33), while in others a negative impact of male gender was not observed (6, 8, 34, 35).”
Tucker, D. W., Getchell, C. R., McCarthy, E. T., Öhman, A., Sasamoto, N., Xu, S., Ko, J. Y., Gupta, M., Shafrir, A. L., Medina, J. E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1958 · Cited by 97
“The use of DNMTis, such as 5aza (44, 45), currently used clinically as Vidaza to treat myelodysplastic syndrome (MDS), may provide benefit to HGSOC patients with 5-hmC loss and intrinsic platinum-resistant disease.”
MethodChronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management
Patnaik, M. M., & Tefferi, A. (2024) · American Journal of Hematology · doi:10.1002/ajh.27271 · Cited by 102
Epigenetic-Based Therapies in Cancer
Song, S., Han, S., & Bang, Y. (2011) · Drugs · doi:10.2165/11596690-000000000-00000 · Cited by 98
“A subsequent international phase III study was designed to detect improvement in OS with azacitidine compared with conventional care without allowing crossover.([54]) A total of 358 patients with MDS were randomly assigned to receive azacitidine (n= 179) at a dose of 75mg/m(2) for 7 days on a 28-day cycle or conventio…”
MethodGuidelines for the diagnosis and management of adult myelodysplastic syndromes
Killick, S. B., Carter, C., Culligan, D. J., Dalley, C. D., Das-Gupta, E. P., Drummond, M. W., Enright, H., Jones, G. L., Kell, J., Mills, J., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12694 · Cited by 97
“Whilst azacitidine has been shown to be effective in all cytogenetic subgroups, comparison with conventional care regimens highlights that patients with isolated -7/del7q have a median OS of 13 1 months with azacitidine versus 4 6 months for conventional care (Fenaux et al, 2009).”
BackgroundInfluentialSelf-citationPrébet, T., Sun, Z., Ketterling, R. P., Zeidan, A. M., Greenberg, P. L., Herman, J. G., Juckett, M., Smith, M. R., Malick, L., Paietta, E. M., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13832 · Cited by 99
Self-citationDickinson, M. J., Cherif, H., Fenaux, P., Mittelman, M., Verma, A. K., Portella, M. S. O., Burgess, P., Ramos, P. M., Choi, J., & Platzbecker, U. (2018) · Blood · doi:10.1182/blood-2018-06-855221 · Cited by 96
Self-citationAggarwal, S., van de Loosdrecht, A. A., Alhan, C., Ossenkoppele, G. J., Westers, T. M., & Bontkes, H. J. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08683.x · Cited by 99
Tan, P., Wei, A. H., Mithraprabhu, S., Cummings, N. J., Liu, H. B., Perugini, M., Reed, K., Avery, S., Patil, S., Walker, P., et al. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2013.68 · Cited by 95
Su, Y., Hickey, S. F., Keyser, S. G. L., & Hammond, M. C. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b01621 · Cited by 95
Garcia‐Manero, G., Roboz, G. J., Walsh, K. J., Kantarjian, H. M., Ritchie, E. K., Kropf, P. L., O'Connell, C. L., Tibes, R., Lunin, S. D., Rosenblat, T. L., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30029-8 · Cited by 95
Platzbecker, U., Schetelig, J., Finke, J., Trenschel, R., Scott, B. L., Kobbe, G., Schaefer‐Eckart, K., Bornhäuser, M., Itzykson, R., Germing, U., et al. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.05.003 · Cited by 94
“Myelodysplastic syndrome (MDS) occurs primarily in older individuals, in whom treatment with hypomethylating agents (HMA) such as azacitidine (AZA) is associatedwith a survival advantage compared with patients treated with supportive care [1,2].”
BackgroundResultSelf-citationGriffiths, E. A., Srivastava, P., Matsuzaki, J., Brumberger, Z. L., Wang, E. S., Kocent, J., Miller, A., Roloff, G. W., Wong, H. Y., Paluch, B. E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1792 · Cited by 94
“Nonintensive therapy with azanucleosides (azacitidine and decitabine) has demonstrated a survival advantage in patients with MDS (4, 5).”
BackgroundGarcia‐Manero, G., McCloskey, J. K., Griffiths, E. A., Yee, K. W. L., Zeidan, A. M., Al‐Kali, A., Deeg, H. J., Patel, P. A., Sabloff, M., Keating, M., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00338-1 · Cited by 94
A chemical probe toolbox for dissecting the cancer epigenome
Shortt, J., Ott, C. J., Johnstone, R. W., & Bradner, J. E. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2016.148 · Cited by 94
Zeidan, A. M., Wang, R., Wang, X., Shallis, R. M., Podoltsev, N. A., Bewersdorf, J. P., Huntington, S. F., Neparidze, N., Giri, S., Gore, S. D., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001779 · Cited by 93
Self-citationValencia, A., Masala, E., Rossi, A., Martino, A., Sanna, A., Buchi, F., Canzian, F., Cilloni, D., Gaidano, V., Voso, M. T., et al. (2013) · Leukemia · doi:10.1038/leu.2013.330 · Cited by 94
Self-citationRavandi, F., Issa, J. J., Garcia‐Manero, G., O'Brien, S. M., Pierce, S. A., Shan, J., Borthakur, G. M., Verstovšek, S., Faderl, S. H., Cortes, J. E., et al. (2009) · Cancer · doi:10.1002/cncr.24661 · Cited by 91
Epigenetic regulators in cancer therapy and progression
Marei, H. E. S. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01003-7 · Cited by 116
Molecular Pathophysiology of Myelodysplastic Syndromes
Lindsley, R. C., & Ebert, B. L. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132436 · Cited by 88
Gailhouste, L., Liew, L. C., Hatada, I., Nakagama, H., & Ochiya, T. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0487-z · Cited by 97
Acetylation- and Methylation-Related Epigenetic Proteins in the Context of Their Targets
Javaid, N., & Choi, S. (2017) · Genes · doi:10.3390/genes8080196 · Cited by 97
DNA–Protein Crosslinks and Their Resolution
Weickert, P., & Stingele, J. (2022) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-032620-105820 · Cited by 96
Bazinet, A., Darbaniyan, F., Jabbour, E. J., Bravo, G. M., Ohanian, M. N., Chien, K. S., Kadia, T. M., Takahashi, K., Masárová, L., Short, N. J., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00216-2 · Cited by 89
Li, H., Hu, F., Gale, R. P., Sekeres, M. A., & Liang, Y. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00402-5 · Cited by 96
How I treat patients with myelodysplastic syndromes
Stone, R. M. (2009) · Blood · doi:10.1182/blood-2008-09-038935 · Cited by 90
Epigenetic modulators as therapeutic targets in prostate cancer
Graça, I. C. R., Pereira-Silva, E., Henrique, R., Packham, G., Crabb, S. J., & Jerónimo, C. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0264-8 · Cited by 90
“Indeed, six epigenetic compounds that target either DNA methylation or histone deacetylation have already been approved by the Food and Drug Administration (FDA) for cancer treatment (Table 1) [62–68].”
Backgroundon behalf of the EORTC Leukemia Group and the German MDS Study Group, Lübbert, M., Suciu, S., Hagemeijer, A., Rüter, B. H., Platzbecker, U., Giagounidis, A. A. N., Selleslag, D., Labar, B., Germing, U., et al. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2547-0 · Cited by 88
“Equally notable was the recurrent observation of activity of DAC [13, 15–18] and azacytidine [10, 19] in MDS/AML patients with sole monosomy 7—also a robust”
Self-citationEpigenetic therapy: azacytidine and decitabine in acute myeloid leukemia
Bohl, S., Bullinger, L., & Rücker, F. G. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1453802 · Cited by 88
“In contrast to chemotherapy, for which a rapid response is expected, response to HMAs is barely seen after one cycle and rather develops over time [18].”
BackgroundSteensma, D. P. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.04.001 · Cited by 91
“For lower-risk patients, commongoals of therapy include symptom control and quality of life, improvement of hematopoiesis, and delay of disease progression.(49,50) For higher-risk patients, extension of survival has been reported with azacitidine therapy.”
BackgroundMethodDietary polyphenols and chromatin remodeling
Russo, G. L., Vastolo, V., Ciccarelli, M., Albano, L., Macchia, P. E., & Ungaro, P. (2015) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2015.1062353 · Cited by 90
“…is one of the many phytoestrogens contained in soybeans and it is becoming clear that its chemopreventive effect on cancer cell growth derives from its ability to inhibit the DNMT activity, and for this reason, it can be used as antineoplastic drug in some malignancies (Fenaux et al., 2009).”
BackgroundAzad, N. S., El-Khoueiry, A. B., Yin, J., Oberg, A. L., Flynn, P. J., Adkins, D., Sharma, A. R., Weisenberger, D. J., Brown, T. D., Medvari, P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15108 · Cited by 88
Fredly, H., Gjertsen, B. T., & Bruserud, Ø. (2013) · Clinical Epigenetics · doi:10.1186/1868-7083-5-12 · Cited by 87
Current therapy of myelodysplastic syndromes
Zeidan, A. M., Linhares, Y. P. L., & Gore, S. D. (2013) · Blood Reviews · doi:10.1016/j.blre.2013.07.003 · Cited by 87
“The clinical benefit associatedwith azacitidine in AZA 001 trial wasmaintained irrespective of the karyotype [118].”
BackgroundInfluentialSelf-citationBCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients
Cluzeau, T., Robert, G., Mounier, N., Karsenti, J. M., Dufies, M., Puissant, A., Jacquel, A., Renneville, A., Preudhomme, C., Cassuto, J. P., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.481 · Cited by 93
“MDS or AML patients treated with AZA are either primary refractory (AZA-resistant) or AZAsensitive but systematically relapse upon treatment with various time lapses[2].”
Epigenetic therapy combinations in acute myeloid leukemia: what are the options?
Bewersdorf, J. P., Shallis, R. M., Stahl, M. F., & Zeidan, A. M. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620718816698 · Cited by 88
Epigenetic Deregulation of Apoptosis in Cancers
Ozyerli‐Goknar, E., & Onder, T. B. (2021) · Cancers · doi:10.3390/cancers13133210 · Cited by 94
Gang, A. O., Frøsig, T. M., Brimnes, M. K., Lyngaa, R., Treppendahl, M. B., Grønbæk, K., Dufva, I. H., Straten, P. T., & Hadrup, S. R. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2014.14 · Cited by 86
Decitabine in the treatment of acute myeloid leukemia in elderly patients
Cashen, A. F., & Malik, P. (2014) · Cancer Management and Research · doi:10.2147/cmar.s40600 · Cited by 86
Govindaraj, C., Tan, P. T., Walker, P., Wei, A. H., Spencer, A. G., & Plebanski, M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1576 · Cited by 86
Therapy with azanucleosides for myelodysplastic syndromes
Quintás‐Cardama, A., Santos, F. P. S., & Garcia‐Manero, G. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.87 · Cited by 85
“The impact of 5-azacitidine on survival was investigated in the international phase III AZA-001 trial”
BackgroundZeidan, A. M., Sekeres, M. A., Garcia‐Manero, G., Steensma, D. P., Zell, K., Barnard, J., Ali, N. E. A., Zimmerman, C., Roboz, G. J., Dezern, A. E., et al. (2015) · Leukemia · doi:10.1038/leu.2015.283 · Cited by 85
Self-citationDigging deep into “dirty” drugs – modulation of the methylation machinery
Pleyer, L., & Greil, R. (2015) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.995379 · Cited by 84
“Almost 35 years later, both drugs have shown significant clinical benefits with high overall response rates and improved overall survival in patients with myeloid malignancies (Fenaux et al., 2009, 2010; Kantarjian et al., 2012; Pleyer et al., 2013, 2014a, b).”
BackgroundInfluentialSelecting initial treatment of acute myeloid leukaemia in older adults
Podoltsev, N. A., Stahl, M. F., Zeidan, A. M., & Gore, S. D. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.09.005 · Cited by 85
Self-citationSchroeder, T. A., Wegener, N., Lauseker, M., Rautenberg, C., Nachtkamp, K., Schuler, E., Kondakci, M., Haas, R. R., Germing, U., & Kobbe, G. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.03.011 · Cited by 83
Epigenetics in the hematologic malignancies
Fong, C. Y., Morison, J., & Dawson, M. A. (2014) · Haematologica · doi:10.3324/haematol.2013.092007 · Cited by 87
Blum, W. G., Sanford, B. L., Klisovic, R. B., DeAngelo, D. J., Uy, G. L., Powell, B. L., Stock, W., Baer, M. R., Kolitz, J. E., Wang, E. S., et al. (2016) · Leukemia · doi:10.1038/leu.2016.252 · Cited by 84
Phillips, C. M., Parmar, A., Guo, H., Schwartz, D., Isaranuwatchai, W., Beca, J. M., Dai, W. F., Arias, J., Gavura, S., & Chan, K. (2020) · Cancer · doi:10.1002/cncr.32697 · Cited by 85
5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft
Lohmeyer, J. K., Bertz, H., Wäsch, R., Marks, R., Zeiser, R., Bogatyreva, L., Finke, J., & Lübbert, M. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.10 · Cited by 83
Myelodysplastic syndromes: 2012 update on diagnosis, risk‐stratification, and management
Garcia‐Manero, G. (2012) · American Journal of Hematology · doi:10.1002/ajh.23264 · Cited by 82
Novel drugs for older patients with acute myeloid leukemia
Bravo, G. M., & Garcia‐Manero, G. (2014) · Leukemia · doi:10.1038/leu.2014.244 · Cited by 82
Platzbecker, U., Hofbauer, L. C., Ehninger, G., & Hölig, K. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.01.006 · Cited by 82
Wolff, F., Leisch, M., Greil, R., Risch, A., & Pleyer, L. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-017-0168-z · Cited by 85
Metadata
- Authors
- Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., Gore, S. D., Seymour, J. F., Bennett, J. M., Byrd, J., Backstrom, J., Zimmerman, L., McKenzie, D., Beach, C., & Silverman, L. R.
- Affiliations
- Université Sorbonne Paris Nord (FR)
- King's College Hospital (GB)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- University Hospital Schleswig-Holstein (DE)
- Düsseldorf University Hospital (DE)
- Hospital Universitari i Politècnic La Fe (ES)
- Moffitt Cancer Center (US)
- Johns Hopkins University (US)
- Karolinska University Hospital (SE)
- University of Rochester Medicine (US)
- The Ohio State University (US)
- Celgene (United States) (US)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Fenaux, Pierre
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2009-03
- Volume
- 10
- Issue
- 3
- Pages
- 223-232
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC4086808
- OpenAlex
- W2118771330
- Cited by
- 2,663
- References
- 45
- Citations by year
- 2026: 80 · 2025: 99 · 2024: 103 · 2023: 153 · 2022: 149 · 2021: 182 · 2020: 148 · 2019: 149 · 2018: 132 · 2017: 164 · 2016: 178 · 2015: 173 · 2014: 201 · 2013: 182 · 2012: 178
- FWCI
- 124.66
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Florence Research (University of Florence) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Research Portal (King's College London) (submittedVersion)
- Funders
- Celgene
- National Cancer Institute (K24CA111717)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- azacitidine, myelodysplastic syndrome, high-risk myelodysplastic syndrome, overall survival, low-dose cytarabine, intensive chemotherapy, best supportive care, hypomethylating agents, treatment efficacy comparison, hematologic malignancies
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antimetabolites, Antineoplastic, Azacitidine, Female, Humans, Male, Middle Aged, Myelodysplastic Syndromes, Proportional Hazards Models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
